Cassiopea Hails Breezula's 'Good Hair Day' And Plans FDA Talks On Phase III
Italy-based Cassiopea says “very positive results” from Breezula's 12-month Phase II alopecia trial support progressing it to Phase III, particularly given the clean safety profile.
You may also be interested in...
Allergan has tried to go after alopecia in the past; Exicure brings a new spherical nucleic acid (SNA) technology. In other recent deals, AstraZeneca sells Seroquel, Losec rights to Germany’s Cheplapharm.
The Italian-headquartered, Swiss-listed company spun out of Cosmo Pharmaceuticals has moved a step closer to having the first topical anti-androgen drug approved for acne.
Evotec is building a gene therapy R&D center manned by ex-Takeda scientists and has already landed a multi-year drug discovery pact for it with their former Japanese employer.